-
Sep 6, 2024 | 
physiciansweekly.com | Kristin Hsieh |Rebecca Shover
Researchers reviewed NCCN guidelines on adjuvant radiotherapy for endometrial cancer, advising physicians on how to tailor treatment to specific cases. A research team from the Icahn School of Medicine at Mount Sinai shared relevant clinical and patient considerations for clinicians to optimize radiotherapy for endometrial cancer. The authors published their narrative review in Cancers.
-
Mar 29, 2024 | 
mdpi.com | Kristin Hsieh |Julie Bloom |Daniel Dickstein
All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.
-
Feb 20, 2024 | 
cco.amegroups.org | Kristin Hsieh |Alexandra Hotca |Juliana Runnels |Daniel Cherry
Have a website account?Log In orRegister for exclusive website content. Home / Publish Ahead of Print / The effects of radiation therapy on the heart: implications for management PDF 2 views Peer Review File 1 views COI Form 1 views
-
Jan 31, 2024 | 00014-9/fulltext&sz=64)
advancesradonc.org | Kristin Hsieh |Julie Bloom |Brianna Jones |Celina Hsieh
AbstractWomen are underrepresented in academic radiation oncology (RO), particularly in leadership positions. In this study, we sought to better understand the characteristics of individuals who currently serve as academic RO chairpersons at institutions with an associated ACGME-accredited RO residency training program.
-
Jan 11, 2024 | 
mdpi.com | Julie Bloom |Carlos A. Rodriguez-Russo |Kristin Hsieh |Daniel Dickstein
All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.
-
Dec 15, 2023 | 
mdpi.com | Catherine Yu |Kristin Hsieh |Daniel Cherry |Anthony D. Nehlsen
All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.
-
Dec 8, 2023 | 00246-4/fulltext&sz=64)
advancesradonc.org | Kristin Hsieh |Alexandra Hotca |Daniel Dickstein |Eric J. Lehrer
1Dickstein DR, Egerman M, Monrose E, et al. Treatment tolerability and outcomes in elderly patients with head and neck cancer. Head Neck. 2021;43(3):858-873. doi:10.1002/hed.265482Aupérin A. Epidemiology of head and neck cancers: an update. Curr Opin Oncol. 2020;32(3):178-186. doi:10.1097/CCO.00000000000006293Cramer JD, Burtness B, Le QT, Ferris RL. The changing therapeutic landscape of head and neck cancer. Nat Rev Clin Oncol. 2019;16(11):669-683.
-
Jul 25, 2023 | 
mdpi.com | Juliana Runnels |Julie Bloom |Kristin Hsieh |Daniel Dickstein
4. DiscussionThe use of both radiotherapy and immunotherapy has shown great promise as a treatment strategy for patients with LA and recurrent/metastatic HNSCC. Several studies have explored the combined synergistic and therapeutic effects of these treatments, providing various mechanistic rationales for their effectiveness. Based on several phase II/III clinical trials, it appears that adding immunotherapy to radiation is a safe option.
-
Jun 6, 2023 | 
mdpi.com | Kristin Hsieh |Daniel Dickstein |Eric J. Lehrer |Juliana Runnels
Abstract:The emergence of immune checkpoint inhibitors (ICIs) as a pillar of cancer treatment has emphasized the immune system’s integral role in tumor control and progression through cancer immune surveillance. ICIs are being investigated and incorporated into the treatment paradigm for lung cancers across stages and histology.
